A 62-year-old man is evaluated for sudden-onset shortness of breath and right-sided pleuritic chest pain. He was admitted 6 days ago for an emergent exploratory laparotomy due to a small bowel obstruction. Following the surgery, he was started on subcutaneous unfractionated heparin for deep vein thrombosis prophylaxis.
On physical examination, his temperature is (), heart rate is , blood pressure is , respiratory rate is , and oxygen saturation is on room air. The lungs are clear to auscultation bilaterally. The right calf is edematous, erythematous, and tender to palpation. The abdominal incision is clean and intact.
Laboratory results are as follows:
| Parameter | Admission | Current |
|---|---|---|
| Hemoglobin | ||
| Leukocyte count | ||
| Platelet count | ||
| Creatinine |
Which of the following is the most appropriate next step in management?
- Discontinue unfractionated heparin and initiate a direct thrombin inhibitorCevap
- BAdminister intravenous furosemide and inhaled bronchodilators
- CArrange for an emergent exploratory laparotomy to evaluate for bowel ischemia
- DOrder a computed tomography scan of the abdomen and pelvis to evaluate for a postoperative abscess
- EInitiate broad-spectrum intravenous antibiotics for presumed hospital-acquired pneumonia
Cevap
Discontinue unfractionated heparin and initiate a direct thrombin inhibitor
The correct action is to discontinue unfractionated heparin and initiate a direct thrombin inhibitor. This patient is presenting with a classic case of Heparin-Induced Thrombocytopenia (HIT), which is characterized by the '4Ts': significant Thrombocytopenia (typically a >50% drop from baseline), Timing (onset 5-10 days after heparin exposure), Thrombosis (new arterial or venous clots, such as his DVT and PE), and the absence of oTher clear causes. HIT is caused by IgG autoantibodies targeting the heparin-platelet factor 4 (PF4) complex. This immune complex activates platelets, leading to massive platelet consumption and a paradoxical, highly prothrombotic state. The most critical initial step in management is the immediate cessation of all heparin products (including low-molecular-weight heparin, which cross-reacts) and the initiation of a non-heparin anticoagulant, such as a direct thrombin inhibitor (e.g., argatroban, bivalirudin) or fondaparinux, to prevent further fatal thromboses.
Adım Adım Çözüm
Anahtar Kavram
Diagnosis and management of Heparin-Induced Thrombocytopenia (HIT)
Tahmini Süre:1m 30s